Last reviewed · How we verify
HyperAcute-Pancreatic Cancer Vaccine
At a glance
| Generic name | HyperAcute-Pancreatic Cancer Vaccine |
|---|---|
| Sponsor | NewLink Genetics Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Digital Strategies to Advance Help-Seeking - Aim 3 (NA)
- Dietary Programme and Exercise Training in Combination or Separately on Managing Sarcopenic Obesity in Older Adults (NA)
- TotalCardiology Letters Study (NA)
- Hypiend - Multicomponent Behavioral Intervention in Pre-puberal Children (Hypiend-PPC) (NA)
- PURI-PRO - Symptoms Impact and eHealth Intervention for Menopausal Women With Urinary Incontinence (NA)
- QT-Digital Mental Health Engagement Study (NA)
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis (NA)
- Behavioral Intervention for PrEP Service Utilization Among Chinese MSM: A HAPA and CEI Integrated Model (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: